To determine the effect renin-angiotensin system blockers on the outcome in patients with hypertension and concurrent COVID-19 infection, we searched PubMed, the Cochrane Library, and Google Scholar for relevant articles. Twelve studies with a total of 16,101 patients met the inclusion criteria. The mortality rate among the users of angiotensin converting enzyme inhibitors or angiotensin receptor blockers was 12.15% and in non-users it was 14.56% (risk ratio 0.70, 95% CI [0.53-0.91], P < 0.007). There was no difference in the risk of death between the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (risk ratio 1.09, 95% CI [0.90 -1.32]). We conclude that the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers improves mortality in patients with hypertension and concurrent COVID-19 infection, without a significant difference between ACEIs and ARBs in this population.
【저자키워드】 COVID-19, hypertension, renin-angiotensin-aldosterone system, 【초록키워드】 Mortality, risk, outcome, renin-angiotensin system, ARB, COVID-19 infection, Patient, mortality rate, inhibitor, ACEi, angiotensin receptor blocker, Google Scholar, risk of death, significant difference, 95% CI, enzyme, no difference, inclusion criteria, Cochrane Library, blocker, articles, IMPROVE, searched, determine, 【제목키워드】 System,